Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schwarzinger

Showing results (301-310 of 359) with videos related to

Pageof 36
Sort By:
Annals of Hematology|August 29, 2020
Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH networkWolfgang Füreder, W R Sperr, S Heibl, et al.
European Journal of Clinical Investigation|August 31, 2007
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapyK J Aichberger, S Herndlhofer, H Agis, et al.
Journal of Hepatology|March 22, 2014
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141)Sylvie Deuffic-Burban, Michaël Schwarzinger, Dorothée Obach, et al.
Leukemia Research Reports|March 6, 2014
FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816HPeter Valent, Katharina Blatt, Gregor Eisenwort, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2009
Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trialCatherine Cordonnier, Cécile Pautas, Sébastien Maury, et al.
Annals of Hematology|May 10, 2003
Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromesA Berer, E Jäger, V Sagaster, et al.
Haematologica|October 14, 2011
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinHarald Herrmann, Sabine Cerny-Reiterer, Karoline V Gleixner, et al.
Wiener Klinische Wochenschrift|April 29, 1998
Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosisF Wimazal, S Walchshofer, M Baghestanian, et al.
Bioconjugate Chemistry|August 28, 2013
Reversible biofunctionalization of surfaces with a switchable mutant of avidinPhilipp Pollheimer, Barbara Taskinen, Andreas Scherfler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot studyK Laczika, M Novak, B Hilgarth, et al.
Pageof 36

Showing results (301-310 of 359) with videos related to

Sort By:
Pageof 36
Annals of Hematology|August 29, 2020
Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH networkWolfgang Füreder, W R Sperr, S Heibl, et al.
European Journal of Clinical Investigation|August 31, 2007
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapyK J Aichberger, S Herndlhofer, H Agis, et al.
Journal of Hepatology|March 22, 2014
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141)Sylvie Deuffic-Burban, Michaël Schwarzinger, Dorothée Obach, et al.
Leukemia Research Reports|March 6, 2014
FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816HPeter Valent, Katharina Blatt, Gregor Eisenwort, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2009
Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trialCatherine Cordonnier, Cécile Pautas, Sébastien Maury, et al.
Annals of Hematology|May 10, 2003
Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromesA Berer, E Jäger, V Sagaster, et al.
Haematologica|October 14, 2011
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinHarald Herrmann, Sabine Cerny-Reiterer, Karoline V Gleixner, et al.
Wiener Klinische Wochenschrift|April 29, 1998
Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosisF Wimazal, S Walchshofer, M Baghestanian, et al.
Bioconjugate Chemistry|August 28, 2013
Reversible biofunctionalization of surfaces with a switchable mutant of avidinPhilipp Pollheimer, Barbara Taskinen, Andreas Scherfler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot studyK Laczika, M Novak, B Hilgarth, et al.
Pageof 36